drugset / Trial / NCT00312351

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

NCT00312351

Phase 4 Terminated 262 enrolled Eyetech Pharmaceuticals Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.

Timeline

Start
2006-04
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer Intravitreal

Indications